Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
Brief Summary: This is a Phase I, open label, dose escalation study of oral administration of MLN0128 in combination with paclitaxel, with/without trastuzumab, in participants with advanced solid malignancies.


Options:
A: Arm Label: Arm A, - Modified DCF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin | Arm Label: ARM B - Parent DCF with G-CSF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen | Arm Label: Arm C - Modifid DCF + Trastuzumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab | Intervention Type: DRUG; Name: Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Assigned to Arm(s): Arm A, - Modified DCF | Intervention Type: DRUG; Name: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen; Assigned to Arm(s): ARM B - Parent DCF with G-CSF | Intervention Type: DRUG; Name: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab; Assigned to Arm(s): Arm C - Modifid DCF + Trastuzumab
B: Arm Label: ECX; Type: EXPERIMENTAL; Interventions: Drug: Epirubicin, Drug: Cisplatin, capecitabine | Arm Label: CX; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, capecitabine | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): ECX | Intervention Type: DRUG; Name: Cisplatin, capecitabine; Assigned to Arm(s): CX, ECX
C: Arm Label: Standard taxane therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Taxane | Arm Label: trastuzumab emtansine 2.4 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Arm Label: trastuzumab emtansine 3.6 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Intervention Type: DRUG; Name: Taxane; Assigned to Arm(s): Standard taxane therapy | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 3.6 mg | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 2.4 mg
D: Arm Label: MLN0128P 30 mg QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 40 mg QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 6 mg QD×3d QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 7 mg QD×3d QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 8 mg QD×3d QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 9 mg QD×3d QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 10 mg QD×3d QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 7 mg QD×5d QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 8 mg QD×3d QW HER2-; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128PH 8 mg QD×3d QW HER2+; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel, Drug: trastuzumab | Intervention Type: DRUG; Name: MLN0128; Assigned to Arm(s): MLN0128P 10 mg QD×3d QW, MLN0128P 30 mg QW, MLN0128P 40 mg QW, MLN0128P 6 mg QD×3d QW, MLN0128P 7 mg QD×3d QW, MLN0128P 7 mg QD×5d QW, MLN0128P 8 mg QD×3d QW, MLN0128P 8 mg QD×3d QW HER2-, MLN0128P 9 mg QD×3d QW, MLN0128PH 8 mg QD×3d QW HER2+ | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): MLN0128P 10 mg QD×3d QW, MLN0128P 30 mg QW, MLN0128P 40 mg QW, MLN0128P 6 mg QD×3d QW, MLN0128P 7 mg QD×3d QW, MLN0128P 7 mg QD×5d QW, MLN0128P 8 mg QD×3d QW, MLN0128P 8 mg QD×3d QW HER2-, MLN0128P 9 mg QD×3d QW, MLN0128PH 8 mg QD×3d QW HER2+ | Intervention Type: DRUG; Name: trastuzumab; Assigned to Arm(s): MLN0128PH 8 mg QD×3d QW HER2+

Answer: D